ArticleWorld journal of urology2020
Centralization tendencies of retroperitoneal lymph node dissection for testicular cancer in Germany? A total population-based analysis from 2006 to 2015.
Article in World journal of urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Robotic assisted versus non-robotic retroperitoneal lymph node dissection for testicular cancer: an updated systematic review and meta-analysis.Journal of robotic surgery · 2026Pooled it
- Robot-assisted retroperitoneal lymph node dissection in testicular cancer: state of the art and future perspectives.Journal of robotic surgery · 2025Review
- [Retroperitoneal lymphadenectomy (RPLND) for the treatment of testicular germ cell tumors-open or robotic? Pro open surgery : RPLND in the management of testis cancer].Urologie (Heidelberg, Germany) · 2025Review
- The perioperative outcomes of retroperitoneal lymph node dissection in Germany for patients with testicular cancer: Results from the GRAND study.International journal of cancer · 2025Article
- Between the Devil and the Deep Sea-The Cardiac Conundrum: Report of a Contiguous Cavo-Atrial Tumor Thrombus in NSGCT Testis.Indian journal of surgical oncology · 2025Article
- Defining a threshold for safe surgical management of vena cava thrombus in renal cell carcinoma patients: evidence from German total population data with 3,700 cases from 2006 to 2020.World journal of urology · 2024Article
- Lymph Node Dissection in Testicular Cancer: The State of the Art and Future Perspectives.Current oncology reports · 2024Review
- The prognostic impact of treatment centralization in patients with testicular germ cell tumors: analysis of hospital-based cancer registry data in Japan.International journal of clinical oncology · 2024Article
- Retroperitoneal lymph node dissection for testicular cancer is a demanding procedure: detailed real-life data of complications and additional surgical procedures in 295 cases.World journal of urology · 2023Article
- Canadian Urological Association consensus guideline: Management of testicular germ cell cancer.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2022Article
- Development of Incidence and Surgical Treatment of Penile Cancer in Germany from 2006 to 2016: Potential Implications for Future Management.Annals of surgical oncology · 2021Article
- [Health care reality of selected pediatric urologic surgeries in Germany from 2006 to 2019].Der Urologe. Ausg. A · 2021Article
- [Trends in uro-oncological surgery in Germany-comparative analyses from population-based data].Der Urologe. Ausg. A · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
introductionRetroperitoneal lymph node dissection (RPLND) is a standard treatment in the management of metastatic testicular cancer. Due to modified treatment algorithms, it is becoming less frequent. MATERIALS AND
methodsWe analyzed data from the nationwide German hospital billing database covering 2006-2015. Cases with a testicular cancer diagnosis combined with RPLND were included. We assessed the length of hospital stay (LOS), blood transfusion, and in-hospital mortality stratified for surgical approach, hospital characteristics, and annual caseload. Annual hospital caseload categories were defined as low (< 4), medium (4-10), and high (> 10). We supplemented tumor incidence and staging data from the German cancer registry (60% of population).
results4926 cases were included with decreasing annual caseload numbers from 623 in 2006 to 382 in 2015. The incidence of testicular cancer and higher tumor stages remained stable. High-volume hospitals performed 19.4%, medium-volume hospitals 43.7%, and low-volume hospitals 36.8% RPLNDs. Low- abd medium-volume hospitals declined, while high-volume hospitals (n = 5) maintained their annual caseload. Overall in-hospital mortality was 0.47%. Blood transfusion rates were higher in high-volume centers assumedly due to selection of more complex cases. However, high-volume hospitals showed a shorter LOS with 10.5 vs. 11.2 (medium volume), and 12.7 days (low volume).
conclusionTotal numbers of RPLND have declined from 2006 to 2015, while tumor incidences and stages remained fairly stable. Constant reduction of indication in guidelines contributes to this finding. High-volume hospitals achieve shorter hospital stays in spite of assumedly more complex and extensive cases. There is a modest trend towards unregulated centralization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.